Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Alimta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Alimta was produced by Lilly.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s presence in cancer is led by lung cancer chemotherapy drug Alimta (pemetrexed), which brought in $2.1bn in sales last year down from a peak of around $2.8bn

Lilly scores FDA okay for Cyramza in liver cancer

Lilly scores FDA okay for Cyramza in liver cancer Last year sales rose 8% to around $820m making it Lilly’s second-largest cancer drug after $2bn lung cancer blockbuster Alimta (pemetrexed), but it has come under pressure as a

Trulicity’s ascent lifts Lilly

Trulicity’s ascent lifts Lilly The company also recently gained FDA approval for Alimta in combination with Keytruda and platinum chemotherapy for the first-line treatment of patients with metastatic NSCLC with no EGFR or ALK

EMA says Lilly’s Lartruvo should not be prescribed

EMA says Lilly’s Lartruvo should not be prescribed The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets,

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly does have presence in the lung cancer field with Alimta, and as this drug is nearing patent expiry, Loxo should provide the firm with opportunities to seize a share of

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics